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We prospectively investigated the efficacy and safety of combining weekly vinorelbine (VNB) with weekly 24-h infusion of high-dose
5-fluorouracil (5-FU) and leucovorin (LV) in the treatment of patients with advanced breast cancer (ABC). Vinorelbine 25mgm
 2
30-min intravenous infusion, and high-dose 5-FU 2600mgm
 2 plus LV 300mgm
 2 24-h intravenous infusion (HDFL regimen) were
given on days 1 and 8 every 3 weeks. Between June 1999 and April 2003, 40 patients with histologically confirmed recurrent or
metastatic breast cancer were enrolled with a median age of 49 years (range: 36–68). A total of 25 patients had recurrent ABC, and
15 patients had primary metastatic diseases. The overall response rate for the intent-to-treat group was 70.0% (95% CI: 54–84%)
with eight complete responses and 20 partial responses. All 40 patients were evaluated for survival and toxicities. Among a total of
316 cycles of VNB–HDFL given (average: 7.9: range: 4–14 cycles per patient), the main toxicity was Gr3/4 leucopenia and Gr3/4
neutropenia in 57 (18.0%) and 120 (38.0%) cycles, respectively. Gr1/2 infection and Gr1/2 stomatitis were noted in five (1.6%) and
59 (18.7%) cycles, respectively. None of the patients developed Gr3/4 stomatitis or Gr3/4 infection. Gr2/3 and Gr1 hand–foot
syndrome was noted in two (5.0%) and 23 (57.5%) patients, respectively. Gr1 sensory neuropathy developed in three patients. The
median time to progression was 8.0 months (range: 3–25.5 months), and the median overall survival was 25.0 months with a follow-
up of 5.5 to 45þ months. This VNB–HDFL regimen is a highly active yet well-tolerated first-line treatment for ABC.
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Breast cancer is the most common malignancy worldwide and is
the fifth cancer killer in Taiwanese women. Despite adequate
primary treatment with surgical resection and adjuvant chemo-
hormonal therapy, about 25–30 and 75–80% of patients
without and with axillary node involvement at mastectomy,
respectively, will have recurrent and/or metastatic breast cancer
within 10 years of surgery (EBCTCG, 1992a,b, 1998; Horton,
1996). Combination chemotherapy will induce an objective
response in approximately two-thirds of patients previously
unexposed to chemotherapy, but complete eradication of disease
at all sites will occur in less than 20% (Ross et al, 1985; Clavel and
Catimel, 1993).
Among the active chemotherapeutic agents in the treatment of
breast cancer, alkylating agents, anthracyclines, and taxanes are
the main components of most standard regimens. Anthracycline-
based combinations represent a highly active cytotoxic chemother-
apeutic approach to the treatment of advanced breast cancer in the
pre-taxane era (Ross et al, 1985: Clavel and Catimel, 1993). They
are capable of inducing objective responses in 40–70% of patients
(Ross et al, 1985; Clavel and Catimel, 1993). Further, taxane-based
combinations also become major regimens for advanced breast
cancer (Fornier et al, 2001; Buzdar et al, 2002; Davidson, 2002;
Henderson et al, 2003). Among the active agents for advanced
breast cancer, vinorelbine is also highly active both as a single
agent and in combination regimens (Krikorian and Breillout,
1991).
Vinorelbine, a new semisynthetic vinca alkaloid, is well tolerated
with significantly less neurotoxicity than other vinca alkaloids
(vincristine and vinblastine) and a low incidence of subjective
toxicities (Krikorian and Breillout, 1991). Vinorelbine, adminis-
tered weekly as a single agent by an intravenous route, resulted in
major objective response in about 45% of patients. Even in patients
previously exposed to standard chemotherapy, 20–30% achieved a
major objective response (Abeloff, 1995; Fumoleau et al, 1995;
Hortobagyi, 1995; Smith, 1995). It is anticipated that vinorelbine
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swill be increasingly utilised for treating metastatic breast cancer
due to its favourable safety profile, good tolerability, and
promising results in combination with other chemotherapy
agents.
A phase I study suggested that the dose-limiting toxicity of
vinorelbine was leucopenia and primarily neutropenia, and the
maximum tolerated dose in single-agent therapy was 35.4mgm
 2
weekly (Mathe and Reizenstein, 1985). A series of phase II studies
have shown that vinorelbine is a highly effective agent in the
treatment of advanced breast cancer (Canobbio et al, 1989;
Fumoleau et al, 1993; Garcia-Conde et al, 1994; Bruno et al,
1995). As first-line chemotherapy of advanced breast cancer,
vinorelbine was studied in 4 phase II studies including 258 patients
at a dose of 30mgm
 2 weekly (Canobbio et al, 1989; Fumoleau
et al, 1993; Garcia-Conde et al, 1994; Bruno et al, 1995). The overall
response rate was between 44% and 60%. The median duration of
response was between 17.9 and 36 weeks, and median survival
ranged from 50.3 to 73 weeks.
Vinorelbine was also used in combination with other che-
motherapy agents in first-line treatment for advanced breast
cancer. In phase II studies, the combination of doxorubicin
(50mgm
 2 per cycle) (Spielmann et al, 1994) or epirubicin
(90mgm
 2 per cycle) (Baldini et al, 1998) with 25mgm
 2 of
vinorelbine on days 1 and 8 every 3 weeks resulted in a very
impressive activity with an overall response rate of 74% (21%
complete response plus 53% partial response) (Spielmann et al,
1994) and 70.2% (8.5% complete response plus 61.7% partial
response) (Baldini et al, 1998), respectively. However,
dose-limiting grade 4 neutropenia (70%) (Baldini et al,
1998) and treatment-related grade 2–4 cardiotoxicity (10%)
(Spielmann et al, 1994) limited the clinical use of these
combination regimens.
Searching for an effective yet well-tolerated regimen is
mandatory. Among them, 5-fluorouracil (5-FU) is a potentially
relevant candidate agent. 5-Fluorouracil could inhibit thymidylate
synthase (TS) by 5-fluoro-20-deoxyuridine monophosphate
(FdUMP), a major metabolite of 5-FU, which binds to TS and
prevents the formation of thymidine monophosphate (dTMP),
which is an important precursor of thymidine triphosphate
(dTTP), one of the four deoxynucleotides required for DNA
synthesis (Grem et al, 1987; Bertino, 1997). Biochemical modula-
tion of 5-FU by the addition of leucovorin (LV) results in the
stabilisation of a ternary complex among FdUMP, LV, and TS. This
enhances the inhibition of TS, the target enzyme of 5-FU
(Grem et al, 1987; Bertino, 1997). Biochemical modulation of 5-
FU by LV has been shown to have a better response than 5-FU
alone in colorectal cancer (ACCMAP, 1992). A similar modulation
effect of LV on 5-FU has also been shown in breast cancer (Fine
et al, 1994).
In advanced breast cancer, in a phase II study of vinorelbine
administered at an intended dose of 30mgm
 2 on days 1 and 5 in
combination with 5-FU continuous infusion (750mgm
 2 daily for
5 days) every 3 weeks, an overall response rate of 61.6% was
observed (Dieras et al, 1996a). The main toxicities (grades 3 and 4)
were neutropenia (90% of patients), infection (12.7%), and
mucositis (37%). The median response duration and overall
survival were 12.3 and 23 months, respectively. Nole et al (1997)
confirmed similar data in combination with vinorelbine, 5-FU, and
LV with a response rate of 62%. However, the 5-day loading
schedule of 5-FU (50mgm
 2 per day for 5 consecutive days as a
continuous infusion) had significant treatment-related toxicity
(such as 90% grade 3/4 neutropenia and 37% grade 3/4 mucositis,
respectively), which may limit its clinical use (Dieras et al, 1996a).
Searching for an effective yet well-tolerated combination is still
mandatory.
Previously, we demonstrated that weekly 24-h infusion of
high-dose 5-FU and LV (folinic acid), the HDFL regimen
originally described by Ardalan et al (1991), appears to be
particularly useful in gastric cancer (Hsu et al, 1997; Yeh and
Cheng, 1998) and colon cancer (Yeh et al, 1997). We have provided
evidence that prolonged exposure of gastric cancer cells to low
concentration 5-FU for 24h enhances the inhibition of TS, and
thereby increases the cytotoxicity of 5-FU (Yeh et al, 2000b).
Further, an HDFL regimen has repeatedly been demonstrated to
cause minimal myelosuppression and therefore is an ideal
component for combination chemotherapy with other cytotoxic
agents against gastric cancer (Hsu et al, 1997; Yeh et al, 1997; Yeh
and Cheng, 1998). We have also reported on the underlying
mechanism of the low myelotoxicity of HDFL (Yeh et al, 2000a).
In one of our pilot studies, we used an HDFL regimen for the
treatment of advanced breast cancer patients with heavily
pretreated status or recurrence after high-dose chemotherapy with
peripheral stem cells support. Even in this group of patients, an
impressive response rate of 33% was noted.
In this study, we investigated if combination of weekly
vinorelbine and weekly HDFL could be an effective yet well-
tolerated regimen of the first-line treatment for patients with
advanced breast cancer.
PATIENTS AND METHODS
Patients
The chemotherapy was used as the first-line therapy, while
previous postmastectomy adjuvant therapy (e.g., CMF regimens,
anthracycline (doxorubicin, epirubicin)-based regimens, or lower
dose 5-FU (p750mgm
 2 per week)) given beyond 6 months
before study enrolment was acceptable.
Eligibility criteria included (1) pathologically confirmed, recur-
rent or metastatic breast cancer, (2) at least one bidimensional
measurable lesion on imaging studies, (3) ECOG performance
status p2, (4) age between 18 and 75 years, (5) adequate hepatic,
renal, and bone marrow functions, and (6) fasting serum TG (1 day
before the first cycle of chemotherapy) 470mgdl
 1. The lower
limit for serum TG was set to avoid HDFL-related hyperammo-
nemic encephalopathy, which occurs in around 5% of Taiwanese
patients (Yeh and Cheng, 1997). Fasting serum TG level
p70mgdl
 1 is the most important risk factor for HDFL-related
hyperammonemic encephalopathy.
Exclusion criteria included (1) previous treatment with
high-dose 5-FU (X2000mgm
 2 per week), (2) prestudy
fasting serum TG level p70mgdl
 1, (3) pregnant, breast-feeding,
or woman of child-bearing potential without adequate contra-
ception, (4) patients who refused placement of a central venous
indwelling catheter (Port-A catheter) for outpatient chemotherapy,
(4) concurrent or prior malignancy except curatively resected
cervical carcinoma in situ or squamous cell carcinoma of skin, (5)
central nervous system metastases, (6) active infection, and (7)
concurrent treatments that could interfere with the study
evaluation. This study was approved by the ethics committee
of National Taiwan University Hospital and Changhua
Christian Hospital. Signed informed consent was obtained from
all patients.
Study design
This was a prospective phase II clinical trial.
Chemotherapy protocol
On days 1 and 8 of each cycle of chemotherapy, vinorelbine
25mgm
 2 was given as a 30-min intravenous infusion, and
followed by 5-FU 2600mgm
 2 and LV (folinic acid) 300mgm
 2
given as a continuous 24-h intravenous infusion. Treatment was
repeated every 21 days. Treatment consisted of at least two cycles
unless rapid disease progression occurred during treatment.
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sResponse assessment was performed every two cycles. Patients
with complete response, partial response or stable disease (SD)
continued the protocol treatment until intolerable toxicity.
Patients with progressive disease were removed from the protocol
treatment, and received other salvage treatment under the
discretion of the responsible physicians. The response rate
reported was the best tumour response obtained by the study
treatment. Tumour response to the salvage therapy has not been
included in the evaluation of the response rate.
Dose modification
For the first cycle of vinorelbine–HDFL, the following criteria were
necessary: WBC count X4000ml
 1 or ANC X2000ml
 1, platelet
count X100000ml
 1, serum creatinine p1.5mgdl
 1, normal
serum bilirubin level, and transaminases (AST or ALT) p3.5-fold
of the upper normal limits (UNLs) of reference values.
Patients were treated with the next cycle of vinorelbine–HDFL
on day 22 or within a 3-week interval from the previous cycle of
vinorelbine–HDFL. No dose reduction for vinorelbine was allowed.
However, in cases of haematological, hepatic, or neurological
toxicity, schedule modification was recommended as follows.
Haematological toxicity
Schedule modification for vinorelbine was based on blood count
results obtained within 2 days of treatment, according to the
following schedule: if leucopenia and/or thrombocytopenia
pgrade 2 (WBC count X2000ml
 1 and platelet count
X50000ml
 1), no schedule delay was indicated; and if leucopenia
or thrombocytopenia Xgrade 3 (WBC count o2000ml
 1 or
platelet count o50000ml
 1), schedule delay and reassessment
were indicated. If the study treatment could not be administered
after a 3-week interval because of haematological toxicity, the
patient was removed from protocol treatment.
Neurological toxicity
If peripheral neuropathy Xgrade 2, schedule delay and reassess-
ment were indicated. If the study treatment could not be
administered after a 3-week interval because of neurological
toxicity, the patient was removed from protocol treatment.
Patients with pretreatment (before the first cycle of vinorelbine–
HDFL) fasting serum TG level p70mgdl
 1 were not neligible for
this trial (Yeh and Cheng, 1997). If patients developed Xgrade 2
toxicity of state of consciousness, HDFL was discontinued
immediately until complete recovery was achieved under the
best supportive care (Yeh and Cheng, 1997). Upon the altered
state of consciousness, plasma ammonia level, lactic acid
level, arterial blood gas, and complete biochemical screening
(including the TG level) were immediately checked and the
extent of HDFL-related neurotoxicity was documented. In the
subsequent cycles, a 40% dose reduction for both 5-FU and LV was
indicated.
Hepatic toxicity
If total bilirubin or AST/ALT levels were abnormal in the absence
of progressive disease, the following dose modifications were
applied to vinorelbine: (1) pgrade 2 toxicity, that is, total bilirubin
or AST/ALT was 1.26- to 5.0-fold of the UNLs of reference values,
no dose modification was indicated, (2) grade 3 toxicity, that is,
total bilirubin or AST/ALT was 5.1- to 10.0-fold of the UNLs,
schedule delay and reassessment were indicated; and (3) grade 4
toxicity, that is, total bilirubin or AST/ALT was more than 10.0-
fold of the UNLs, vinorelbine was discontinued in the subsequent
cycles.
Other toxicities
When Xgrade 3 diarrhoea or stomatitis developed, HDFL
chemotherapy was temporarily stopped for schedule delay and
was reused after diarrhoea and stomatitis subsided to pgrade 1.
Evaluation of efficacy and toxicities
Evaluations before chemotherapy included medical history taking,
physical examination, complete blood count, blood chemistry,
chest X-ray, and computed tomography (CT) scan of chest or
abdomen as indicators of the location of lesions. After starting
protocol treatment, complete blood count was examined weekly
and blood chemistry every 2 weeks. The patients’ condition and
treatment-related toxicities were evaluated weekly. Tumour size
was measured by imaging studies every two cycles, or when there
were any clinical signs of possible tumour progression. Tumour
response was evaluated according to the World Health Organiza-
tion (WHO) criteria. Toxicities were graded using the NCI-
common toxicity criteria (version 2.0).
Statistical methods
This was a phase II, two-institutional, prospective study. The
Simon two-stage design was used. The response rates of interest
were P0¼50% and P1¼70%. If there were more than 11
responders of the 23 patients in the first stage, the study then
continued to enrol a total of 40 patients. If there were more than 24
responders of the 40 patients, this treatment would be acceptable
with a of 0.10 and b of 0.10. Patients evaluable for response were
those who had finished at least two cycles of treatment. All enrolled
patients were subjected to toxicity evaluation.
Time to progression was defined as the duration from the date
of starting protocol treatment to the date of documented disease
progression or death by any cause. Overall survival was defined as
the duration from the date of starting protocol treatment to the
date of death. The Kaplan–Meier method was used in all survival
analyses.
RESULTS
Patients and treatment
Between June 1999 and April 2003, 40 patients were enrolled in
the study. The major clinicopathologic features of the patients
are listed in Table 1. The median age was 49 years (range: 36–68).
A total of 25 patients had recurrent advanced breast cancer
(15 had prior anthracycline-containing adjuvant chemo-
therapy, two had CMF adjuvant chemotherapy), and 15 patients
had primary metastatic diseases. A total of 10 (25%) patients had
bone/soft tissue disease, and 10 (25%) patients had three or more
sites of metastatic diseases. Eight (20%) patients had had
postmastectomy adjuvant chemotherapy for more than 2 years;
although they were not chemonaive patients, the study regimens
for them were the first-line treatment after metastasis or
recurrence.
A total of 316 cycles (median: 8; mean: 7.9; range: 4–14) of
chemotherapy were given. In all, 107 (33.9%) cycles needed a
median schedule delay of 7 days (range: 3–14 days) mainly due to
grade 3/4 neutropenia.
Efficacy
All 40 patients were evaluated for response. There were 16
responses in 23 patients in the first stage. Therefore, the study
continued to enrol a total of 40 patients as scheduled by the two-
stage design. None of the patients had early progression or
excluded from analysis for tumour response. There were eight
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spatients with complete remission (CR), 20 patients with partial
remission (PR), and 12 patients with SD. The overall response rate
for the intent-to-treat group was 70.0% (95% confidence interval:
54–84%). The median time to tumour response was 1.5 months
(range: 1.5–3.5 months). Four patients (10%) dropped out after
completion of two, four, six, and 12 cycles of study treatment in
response conditions (one CR and three PR) due to treatment
refusal. All of them were included in the survival analysis. None of
the enrolled patients lost to follow-up.
Salvage therapy after disease progression included anthracy-
cline-containing regimens, taxane-based regimens, trastuzumab,
and aromatase inhibitors (anastrozole or letrozole) in nine, 19, six,
and 11 patients, respectively. The median follow-up time of the
whole group of 40 patients was 27 months. The median time to
progression was 8.0 months (range: 3–25.5 months) (Figure 1).
The median overall survival was 25 months (range: 5.5 to 45þ
months) (Figure 2).
Toxicity
All 40 patients were evaluated for toxicities (Table 2). The main
toxicity was grade 3/4 leucopenia and grade 3/4 neutropenia in 57
(18.0%) and 120 (38.0%) cycles, respectively. Grade 1/2 infection
and grade 1/2 stomatitis were noted in five (1.6%) and 59 (18.7%)
cycles, respectively. None of the patients developed grade 3/4
stomatitis or grade 3/4 infection. Grade 3/4 and grade 1/2
diarrhoea was noted in 1 (0.3%) and 26 (8.2%) cycles, respectively.
Grade 2/3 and grade 1 hand–foot syndrome was noted in two
(5.0%) and 23 (57.5%) patients, respectively. One patient needed a
25% dose reduction of 5-FU due to grade 4 diarrhea, and one
patient needed a 40% dose reduction of 5-FU/LV due to
hyperammonemic encephalopathy during the first cycle. Grade 1
sensory neurotoxicity developed in three patients. Other non-
haematological toxicities were negligible. No patients discontinued
protocol treatment because of vinorelbine-related neuropathy. Due
to cautious prestudy screening of fasting serum TG level and
meticulous guidelines for dose modification of 5-FU and LV, only
one of the patients developed HDFL-related hyperammonemic
encephalopathy (Yeh and Cheng, 1997).
Table 1 Clinicopathologic features of the patients
Patient number
Total patients 40
Age, median (range) 49 (36–68)
ECOG performance:
0 10 (25.0%)
1 24 (60.0%)
2 6 (15.0%)
Menopausal status
Premenopause 18 (45.0%)
Postmenopause 22 (55.0%)
Oestrogen receptor status
Positive 21 (52.5%)
Negative 11 (27.5%)
Unknown 8 (20.0%)
Disease status
Recurrence/metastasis 25 (62.5%)
de novo metastasis 15 (37.5%)
Prior therapy
Anthracycline-containing adjuvant chemotherapy 15 (37.5%)
CMF adjuvant chemotherapy 2 (5.0%)
Hormonal therapy 21 (52.5%)
Local radiotherapy 11 (27.5%)
Disease sites
Lymph nodes 33 (82.5%)
Lung 26 (65.0%)
Breast 19 (47.5%)
Bone or/and spine 16 (40.0%)
Liver 12 (30.0%)
Pleural effusion 8 (20.0%)
Skin 6 (15.0%)
Others 1 (2.5%)
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Figure 1 Kaplan–Meier curve for time-to-progression of the 40 patients.
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Figure 2 Kaplan–Meier curve for overall survival of the 40 patients.
Table 2 Toxicity of the vinorelbine–HDFL regimen
Patients (n¼40) Cycles (n¼316)
Toxicity Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Haematological
Neutropenia 17.5% 80.0% 37.7% 38.0%
Leucopenia 47.5% 40.0% 48.2% 18.0%
Thrombocytopenia 10.0% 0 2.5% 0
Febrile neutropenia — 2.5% — 0.3%
Gastrointestinal
Nausea 80.0% 5.0% 49.4% 1.6%
Vomiting 47.5% 10.0% 18.4% 2.2%
Diarrhoea 35.0% 2.5% 8.2% 0.3%
Stomatitis 55.0% 0 18.7% 0
Neuropathy 7.5% 0 3.8% 0
Hepatic 67.5% 2.5% 28.8% 0.3%
Others
Hand–foot syndrome 57.5%
a 5.0%
b NA NA
Infection 5.0% 0 1.6% 0
Alopecia 75.0% 2.5% 54.7% 0.6%
aGrade 1.
bGrade 2–3. NA¼nonapplicable by cycles.
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sDISCUSSION
The results of this phase II study indicated that this vinorelbine–
HDFL regimen using weekly vinorelbine and weekly 24-h infusion
of high-dose 5-FU/LV is effective for the treatment of advanced
breast cancer. The overall response rate of 70.0% (95% confidence
interval: 54–84%) was within the range (40–70%) of previously
reported major protocols of anthracycline-based regimens (Ross
et al, 1985; Clavel and Catimel, 1993; Jassem et al, 2001; Biganzoli
et al, 2002; Sledge et al, 2003), taxane-based regimens (Jassem et al,
2001; Biganzoli et al, 2002; Sledge et al, 2003), and anthracycline-
and-taxane-based regimens (Razis and Fountzilas, 2001; Sledge
et al, 2003). Previously, studies from other series using vinorelbine
and different administration schedules of 5-FU and LV have also
demonstrated a good efficacy in breast cancer (Dieras et al, 1996a;
Nole et al, 1997). However, the 5-day loading schedule of 5-FU
created significant treatment-related toxicity, which may limit its
clinical use (Dieras et al, 1996a). We report that this vinorelbine–
HDFL regimen using a unique schedule of 5-FU and LV is an
effective yet well-tolerated combination for advanced breast
cancer.
In this study, 5-FU and LV were given in two doses of weekly 24-
h infusion (HDFL regimen) every 3 weeks. The rationale for this
scheduling of 5-FU/LV was based on our previous studies, which
indicated that HDFL is in general a highly effective and very safe
regimen for advanced gastric cancer (Hsu et al, 1997; Yeh and
Cheng, 1998) and colorectal cancer (Yeh et al, 1997). In our pilot
studies, we used an HDFL regimen for the treatment of advanced
breast cancer patients with heavily pretreated status or recurrence
after high-dose chemotherapy. Even in this group of patients, an
impressive response rate of 33% was noted.
The patients’ compliance with this HDFL regimen was generally
good. Further, results of our in vitro studies have implied that
strict avoidance of bolus injection of 5-FU is the key to avoiding
myelosuppression (Yeh et al, 2000a). Although the best protocol of
5-FU remains to be explored (Bertino, 1997; Grem, 2001), both
clinical and laboratory data indicate that HDFL is an ideal
component for combination chemotherapy with other cytotoxic
agents. For instance, paclitaxel followed by weekly high-dose 5-FU
and LV infusion has been shown to have a 55% response
rate in anthracycline-resistant metastatic breast cancer patients
(Klaassen et al, 1995, 1996). In this study, we showed that weekly
vinorelbine plus weekly HDFL is an effective regimen with well-
tolerated toxicities for the first-line treatment of advanced breast
cancer.
Although survival is not a major end point for evaluation of
efficacy in phase II trials, the median overall survival of 25 months
in this study was favourably within the range of other previously
reported major protocols of anthracycline-based regimens (Ross
et al, 1985; Clavel and Catimel, 1993; Jassem et al, 2001; Biganzoli
et al, 2002; Sledge et al, 2003), taxane-based regimens (Jassem et al,
2001; Biganzoli et al, 2002; Sledge et al, 2003), and vinorelbine-
based regimens (Dieras et al, 1996a; Nole et al, 1997; Norris et al,
2000).
The toxicity of the current vinorelbine–HDFL protocol is
generally well tolerated. Although vinorelbine-related neurotoxi-
city did occur in this study, it was usually mild (grade 1/2) under
this weekly schedule. No patients discontinued protocol treatment
due to vinorelbine-related neuropathy. In contrast, the paclitaxel-
related neuropathy was found to be one of the dose-limiting
toxicities in paclitaxel-containing regimens for breast cancer
(Postma et al, 1995; Forsyth et al, 1997; Gelmon et al, 1999).
Other major toxicities, including diarrohea and stomatitis, were of
lesser severity than for other major regimens using vinorelbine and
a 5-day schedule of 5-FU and LV (Dieras et al, 1996a; Nole et al,
1997). Neutropenia and leucopenia were not less severe than other
reported regimens using vinorelbine and 5-FU; however, the doses,
schedules, and G-CSF support of these regimens were essentially
different from the current regimen (Kornek et al, 1998; Lombardi
et al, 2000). Regimen used by Kornek et al (1998) required G-CSF
support at 5mgkg
 1 day
 1 subcutaneously on days 6–10 during
each cycle, and it was complicated with septicaemia in two
patients. Regimen used by Lombardi et al (2000) applied lower
dose intensity of vinorelbine (20mgm
 2 on days 1 and 8, every 4
weeks) than current regimen (25mgm
 2 on days 1 and 8, every 3
weeks). In addition, the regimen by Lombardi et al (2000) used
protracted continuous infusion (PCI) of low-dose 5-FU
(250mgm
 2 day
 1) (Lombardi et al, 2000), rather than a
convenient weekly HDFL. Although grade 3/4 neutropenia and
grade 3/4 leucopenia were still common, the rarity of both grade 3/
4 stomatitis and grade 3/4 diarrohea may contribute to the absence
of grade 3/4 infections in this study. Prophylactic G-CSF support
was not used in this study. A total of 117 (33.9%) cycles needed a
median delay of 7 days (range: 3–14 days). Prophylactic
antibiotics with oral quinolones were used in 7.5% of patients.
Overall, the toxicity profiles of the current vinorelbine–HDFL
protocol were generally well tolerated.
We conclude that combination of weekly vinorelbine and weekly
24-h infusion of high-dose 5-FU and LV is a highly effective
regimen with well-tolerated toxicities for the first-line treatment of
advanced breast cancer.
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